Thermo Fisher Scientific Launches CE-IVD Marked Panel to Detect Most Common Gastrointestinal Bacteria

CARLSBAD, Calif.--(BUSINESS WIRE)--Thermo Fisher Scientific, the world leader in serving science, today announced the launch of the TaqPath Enteric Bacterial Select Panel, a CE-IVD marked panel designed to detect common gastrointestinal (GI) bacteria and help enable clinicians to identify the root cause of an infection and administer the most appropriate treatment to their patients more quickly. The panel was validated and registered under IVDD in May 2022.

The new test leverages polymerase chain reaction (PCR) technology to analyze stool samples for a range of common GI bacteria, including Salmonella spp.; Shigella spp./enteroinvasive E. coli (EIEC); Campylobacter jejuni, Campylobacter coli, and Campylobacter upsaliensis. It is able to reliably return results in about two hours with more than 98 percent sensitivity and specificity. In comparison, culturing samples in a laboratory can take up to two weeks to deliver results.

“The TaqPath Enteric Bacterial Select Panel’s ability to identify and differentiate between the most common diarrhea-causing pathogens will make testing more accessible and provide laboratorians with more agility when identifying GI bacteria,” said Dr. Manoj Gandhi, senior medical director of Genetic Testing Solutions at Thermo Fisher Scientific. “Detecting these different pathogens in a single test can preserve precious lab resources while still providing clinicians critical information needed to make the right treatment decisions for their patients.”

Testing using the TaqPath Enteric Bacterial Select Panel can be done in one test tube, and can be scaled up to fit the needs of the lab by enabling up to 93 samples to be tested in one run. When conducted on Thermo Fisher’s QuantStudio 5 and QuantStudio 5 Dx systems, results from samples are interpreted and generated automatically, helping to save laboratorian’s time so they can focus on other tasks.

For more information on the TaqPath Enteric Bacterial Select Panel, please visit www.thermofisher.com/taqpathentericselect

The TaqPath Enteric Bacterial Select Panel is CE marked, For In Vitro Diagnostic Use.

About Thermo Fisher Scientific
Thermo Fisher Scientific Inc. is the world leader in serving science, with annual revenue of approximately $40 billion. Our Mission is to enable our customers to make the world healthier, cleaner and safer. Whether our customers are accelerating life sciences research, solving complex analytical challenges, increasing productivity in their laboratories, improving patient health through diagnostics or the development and manufacture of life-changing therapies, we are here to support them. Our global team delivers an unrivaled combination of innovative technologies, purchasing convenience and pharmaceutical services through our industry-leading brands, including Thermo Scientific, Applied Biosystems, Invitrogen, Fisher Scientific, Unity Lab Services, Patheon and PPD. For more information, please visit www.thermofisher.com.

Media Contact Information:
Mauricio Minotta
Phone: 760-805-5266
E-mail: Mauricio.Minotta@thermofisher.com

Ariane Lovell
Phone: 646-307-6317
Email: Ariane.lovell@finnpartners.com